 |
|
NeuroprotectionChallenges and Opportunities
Alan I. Faden, MD;
Bogdan Stoica, MD
Arch Neurol. 2007;64(6):794-800.
The ability of pharmacological agents to limit secondary biochemical damage and cell death has been well established in numerous animal models of stroke, head injury, and spinal cord injury, yet the results of such neuroprotective treatment strategies in human injury have been disappointing. A number of conceptual and methodological issues have undoubtedly contributed to the difficulties in translating the experimental results to the clinic. Most recently, different experimental approaches and altered clinical trial methodologies have provided renewed, albeit cautious, optimism regarding future clinical trials of neuroprotective agents. Herein, we reviewed both the critical problems and potential solutions, emphasizing recent experimental and clinical work.
Author Affiliations: Department of Neuroscience, Georgetown University Medical Center, Washington, DC.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The nerve injury and the dying neurons: diagnosis and prevention
Terenghi et al.
J Hand Surg Eur Vol 2011;36:730-734.
ABSTRACT
| FULL TEXT
Atherosclerotic Peripheral Vascular Disease Symposium II: Stroke Intervention: State of the Art
Alberts et al.
Circulation 2008;118:2845-2851.
FULL TEXT
Endogenous Neural Progenitor Cells as Therapeutic Target After Spinal Cord Injury
Obermair et al.
Physiology 2008;23:296-304.
ABSTRACT
| FULL TEXT
|
